Pioneer Surgical Technology has announced that its proprietary nanOss Bioactive has undergone successful human implantation in Europe, thus paving the way to international distribution.
The nanOss Bioactive bone graft is composed of proprietary collagen-based biopolymer and nanocrystalline hydroxyapatite to accelerate the growth of bone in the posterolateral spine.
Pioneer Surgical Technology will display this product portfolio at the 2012 Spine Week Conference in Amsterdam, The Netherlands. The company’s Executive Vice President for Biologics, Mr. Shane Ray stated that the company is happy to extend the availability of its flagship product nanOss Bioactive worldwide. Global expansion of the company’s Biologics products is a part of its strategic activity and these new products are a perfect match for the company’s spine products, which are already offered outside the US.
Pioneer Surgical is a research-oriented medical device company specializing in developing distinguished biologic, cardiovascular, orthopedic, and spine products. The company is helping the global development of novel surgical technologies by manufacturing products capable of offering effective procedures for physicians and operating room staff, better patient results, and cost-efficient solutions for the healthcare system.
Pioneer Surgical’s extensive research has resulted in more than 130 United States and foreign patents, of which several patents are in the patent pending status. The company has over 270 employees worldwide. It established its European subsidiary in the Netherlands in the year 2006, and offers its comprehensive portfolio of spine products across Europe through many distributors.